In this work, we have used LNCaP (AR positive, ERα negative) and PC-3 (AR negative, ERα positive) prostate tumour cells to address the mechanism through which RES modulates the AR- and ERα-associated PI3K activity. The gene discussed is ESR1; the disease is prostate neoplasm.